Fazili A, Jazayeri SB, Rose KM, Guske C, Wen LXC, Durant A, Prunty M, Bukavina L, Tyson MD, Grass GD, Xu HZ, Spiess PE, Gilbert SM, Sexton WJ, Zemp L, Pessoa RR, Poch M, Lerner SP, Li R
Abstract
Objectives To compare survival and oncological outcomes of cisplatin-ineligible patients (Cis-I) and cisplatin-eligible (Cis-E) patients with muscle-invasive bladder cancer (MIBC) undergoing immediate radical cystectomy (IRC), as IRC is currently considered the standard-of-care for Cis-I patients with MIBC. Patients and Methods Data from patients with clinical (c)T2-4cN0-1M0 MIBC undergoing IRC, between 2006 and 2021, were retrospectively analysed from four tertiary care centres in the United States. Overall, recurrence-free and event-free survival were described using the Kaplan-Meier method and tested using the log-rank test. For context, we compared survival outcomes against those in Cis-E patients with MIBC undergoing IRC from the Southwest Oncology Group (SWOG)-8710 trial. Results Overall, 379 Cis-I and 125 Cis-E patients with cT2-4cN0-1M0 MIBC who underwent IRC were included. Cis-I patients included 44.8% cT3/4 vs 60% cT3/4 in the Cis-E group. Overall, 83.3% of Cis-I and 79.2% of Cis-E patients died during follow-up. The median event-free survival and overall survival were 14.5 and 60.1 months vs 12.1 and 28.8 months in favour of the Cis-E group (P < 0.001). Limitations include retrospective comparison of contemporary multi-institutional data with that of a randomised control trial. Conclusions The Cis-I patients with MIBC undergoing IRC fared poorly, with a median overall survival of 14.5 (95% confidence interval 11.1-17.9) months, mostly due to non-cancer-related deaths. These results provide a benchmark for clinical trials exploring novel agents or alternative chemotherapy regimens in Cis-I patients with MIBC.
